The Fractalkine-CX3CR1 Axis Regulates Non-inflammatory Osteoclastogenesis by Enhancing Precursor Cell Survival

Area of Science:

• Bone Biology
• Immunology
• Cell Signaling

Background:

• Fractalkine (FKN) is produced in bone by osteoblasts and endothelial cells.
• FKN signals via CX3CR1, found on monocytes, macrophages, and osteoclast precursors (OCPs).
• The role of FKN in OCPs during noninflammatory conditions is not well understood.

Purpose of the Study:

• To investigate the direct effects of FKN on OCP survival and differentiation.
• To determine the therapeutic potential of targeting the FKN-CX3CR1 axis in bone loss.

Main Methods:

• Culturing wild-type and CX3CR1-deficient OCPs on immobilized FKN.
• Stimulating OCPs with receptor activator of NF-κB ligand (RANKL).
• Analyzing osteoclast formation, gene expression (Cx3cr1, Rank), and protein expression (CX3CR1, RANK).
• Utilizing a RANKL-induced mouse model of bone loss and anti-FKN monoclonal antibody (mAb) treatment.

Main Results:

• FKN enhances OCP survival and primes them for RANKL-induced osteoclast differentiation.
• FKN increases Cx3cr1 and Rank expression in OCPs, with Cx3cr1 downregulated post-RANKL stimulation.
• Anti-FKN mAb treatment inhibits OCP differentiation and RANKL-dependent bone loss.

Conclusions:

• FKN signaling is crucial for OCP survival and osteoclastogenesis under noninflammatory conditions.
• Targeting the FKN-CX3CR1 axis offers a potential therapeutic strategy for noninflammatory bone loss.